In Brief: Chiron
Executive Summary
Chiron: Company will take a charge against earnings for the third quarter for the carrying value reduction of its idle fill and finishing facility in Puerto Rico. Appraisal is not complete but Chiron estimates that a $25 mil. write-down will be taken. The company is considering selling the facility. It was built for the manufacture of Betaseron (interferon beta-1b) for Berlex but never went on-line; need for Betaseron did not grow as predicted to require a second facility...